Hypothyroidism

Hypothyroidism became an Agent Orange presumptive condition in 2021 under the Section 1112 expansion. Before then, veterans with hypothyroidism had to prove a direct service connection or run a secondary theory through another presumptive endocrine condition. The expansion changed the math for thousands of Vietnam-era veterans whose claims had been denied under the older framework, and our dataset reflects the post-expansion period where the presumptive lane is doing most of the structural work.

In our analysis of 549 BVA hypothyroidism cases, the grant rate is 40.4 percent. The presumptive lane grants at 64.5 percent (186 cases). The direct lane grants at 38.9 percent (203 cases). Secondary grants at 46.7 percent. The presumptive advantage is roughly 25 percentage points, driven almost entirely by herbicide and Agent Orange cases.

This page covers DC 7903's rating mechanics, the herbicide presumption framework, the Camp Lejeune adjacency, the 30 percent rating tier that most claims land at, and what wins hypothyroidism claims at the Board.

TL;DR

• 549 hypothyroidism cases in our BVA dataset. Outcomes: 40.4% granted, 49.2% denied, 10.4% remanded.
• The symptom-tier ladder was repealed effective 2017-12-10. The current DC 7903 has exactly two rungs: 100% for hypothyroidism manifesting as myxedema, and 30% for hypothyroidism without myxedema. There is no 10% tier and no 60% tier, and no symptom constellation is required for either rung.
• Both rungs are time-limited. The 30% runs six months from initial diagnosis; the 100% runs six months past crisis stabilization. After that VA rates the residual effects under the appropriate diagnostic code in the appropriate body system, so the long-term rating lives in mental disorders, eye, digestive, or cardiovascular, not in the endocrine code.
• Note (3) allows a separate eye rating. Exophthalmos, corneal ulcer, blurred vision, or diplopia due to thyroid disease is evaluated separately under § 4.79, not folded into the thyroid evaluation.
• Hypothyroidism was added to the Agent Orange presumptive list under 38 USC § 1116 in 2021. Veterans with qualifying Vietnam-era service whose claims were denied under the older framework can file supplemental claims under the expanded presumption.
• Presumptive lane grants at 64.5%, overwhelmingly herbicide / Agent Orange (221 of 186 presumptive cases). Camp Lejeune adds 5 cases through a different presumptive framework.
• The modal granted rating is 30 percent (36 cases) and 100 percent shows up in 11 cases, but those decisions applied the pre-2017 ladder. Under the current code 30 percent is close to automatic for six months and then gives way to residuals.
• Strong nexus opinions grant at 97.2 percent. Weak and missing nexus grant at 0 percent.
• The top denial reason is "severity insufficient" at 67 of 220 classified denials, a pattern produced by the old symptom-checklist tiers. Under the current code the equivalent failure is a file that never names the residuals or places them in a body system.

DC 7903 Is Now a Six-Month Placeholder, Not a Symptom Ladder

If you have read almost anything else about hypothyroidism ratings, you have read about a four-tier symptom ladder: 10 percent for fatigability or continuous medication, 30 percent for fatigability plus constipation plus mental sluggishness, 60 percent for muscular weakness plus mental disturbance plus weight gain, and 100 percent for a six-element constellation ending in bradycardia and sleepiness.

That ladder was repealed. VA rewrote the endocrine section effective December 10, 2017, and the current DC 7903 in 38 CFR § 4.119 reads in full:

Hypothyroidism manifesting as myxedema (cold intolerance, muscular weakness, cardiovascular involvement (including, but not limited to hypotension, bradycardia, and pericardial effusion), and mental disturbance (including, but not limited to dementia, slowing of thought and depression)), 100%

Note (1): This evaluation shall continue for six months beyond the date that an examining physician has determined crisis stabilization. Thereafter, the residual effects of hypothyroidism shall be rated under the appropriate diagnostic code(s) within the appropriate body system(s) (e.g., eye, digestive, and mental disorders).

Hypothyroidism without myxedema, 30%

Note (2): This evaluation shall continue for six months after initial diagnosis. Thereafter, rate residuals of disease or medical treatment under the most appropriate diagnostic code(s) under the appropriate body system (e.g., eye, digestive, mental disorders).

Note (3): If eye involvement, such as exophthalmos, corneal ulcer, blurred vision, or diplopia, is also present due to thyroid disease, also separately evaluate under the appropriate diagnostic code(s) in § 4.79, Schedule of Ratings, Eye (such as diplopia (DC 6090) or impairment of central visual acuity (DCs 6061-6066)).

That is the entire code. Two rungs, and the notes matter more than the rungs.

There is no 10 percent tier and no 60 percent tier. Both were deleted. So was every symptom constellation. Fatigability, constipation, mental sluggishness, and weight gain appear nowhere in the current DC 7903, and a claim built on documenting them is documenting a repealed standard.

The 30 percent is close to automatic, and it expires. Hypothyroidism without myxedema rates 30 percent, full stop. No symptom showing is required. But Note (2) runs that evaluation for six months after initial diagnosis, and then it stops being the rating. After six months VA is directed to rate the residuals under whatever body system they fall in.

The 100 percent is narrow, and it also expires. It requires myxedema, which is a specific clinical picture: cold intolerance and muscular weakness and cardiovascular involvement and mental disturbance. Note (1) runs it for six months past crisis stabilization, then the same residual analysis takes over.

What this changes about how you build the claim

The whole center of gravity moved. Under the old rule the fight was about stacking three symptoms into a tier. Under the current rule the endocrine code is a placeholder that pays for roughly six months, and your long-term rating lives in other body systems entirely.

That makes the residual inventory the claim. The regulation names examples, and they are the places to look:

• Mental disorders. Depression, cognitive slowing, and memory complaints attributable to thyroid disease are rated under § 4.130, on the General Rating Formula for Mental Disorders. That formula reaches 100 percent and is where the durable rating usually is.
• Eye. Note (3) is unusually generous and easy to miss. If exophthalmos, corneal ulcer, blurred vision, or diplopia is present due to thyroid disease, it is separately evaluated under § 4.79, in addition to the endocrine rating rather than folded into it.
• Digestive. Persistent constipation or other GI residuals are rated under § 4.114.
• Cardiovascular. Bradycardia, hypotension, or pericardial effusion that persists is rated under § 4.104 rather than counted as an element of a thyroid tier.

A veteran six months past diagnosis whose file contains only "hypothyroidism, on levothyroxine, stable" has nothing for a rater to work with, because the code itself has run out. The record has to name the residuals and place them in a body system.

If your claim spans December 10, 2017, the old symptom-ladder criteria apply to the period before that date and the current criteria from that date forward, with staged ratings where the evidence supports different levels in different periods. Amended criteria are not applied retroactively to an earlier period.

The 2021 Agent Orange Presumption Expansion

Section 1112 of the National Defense Authorization Act for Fiscal Year 2021 added hypothyroidism to the list of presumptive conditions for Vietnam-era veterans exposed to Agent Orange. The expansion was codified through VA regulatory action and is implemented under 38 CFR § 3.309(e).

For veterans with qualifying Vietnam-era service, boots-on-ground in the Republic of Vietnam, offshore-waters service under the Blue Water Navy Vietnam Veterans Act of 2019, or service in certain other locations with documented herbicide exposure, hypothyroidism is now presumed to be related to service.

The qualifying service definition for the Agent Orange presumption has been expanded multiple times. The current framework covers:

• Service in the Republic of Vietnam (including the inland waterways and offshore waters within 12 nautical miles) from January 9, 1962 through May 7, 1975
• Service in the Korean DMZ from September 1, 1967 through August 31, 1971
• Certain service in Thailand from January 9, 1962 through May 7, 1975
• Service in C-123 aircraft at specific locations and time periods
• Other limited contexts with documented herbicide exposure

In our dataset, the 186 presumptive-category cases break down as 178 herbicide and 43 Agent Orange (the same exposure framework coded under different field values). The 64.5 percent grant rate reflects the structural ease of these cases. Once qualifying service is established, the nexus question is presumed.

For veterans whose hypothyroidism claims were denied before the 2021 expansion, the supplemental claim path under 38 CFR § 3.156 is available. Many of these older denials are now eligible for reconsideration.

Camp Lejeune and Other Presumptive Lanes

Beyond the Agent Orange framework, smaller presumptive lanes apply in specific cases:

Camp Lejeune (38 USC § 1710(e) and 38 CFR § 3.307(a)(7)): Service at Camp Lejeune between August 1, 1953 and December 31, 1987, for at least 30 cumulative days. The Camp Lejeune presumptive list doesn't directly include hypothyroidism, but the contaminated water exposure has been associated with various endocrine and metabolic conditions in the broader scientific literature. Some Camp Lejeune-related hypothyroidism claims proceed under direct service connection with the contaminated water as the documented exposure, rather than under the formal presumption.

Radiation exposure (38 CFR § 3.311): Veterans with documented exposure to ionizing radiation during atomic testing, occupation of Hiroshima or Nagasaki, or other specified contexts. Thyroid cancer is on the radiation-exposed list; hypothyroidism is not, but cases involving post-radiation thyroiditis sometimes succeed under direct service connection.

Gulf War undiagnosed illness (38 CFR § 3.317): For veterans with qualifying Southwest Asia service whose symptoms include unexplained fatigue, cognitive symptoms, or weight changes, hypothyroidism can sometimes be analyzed under the chronic multisymptom illness framework, though this is less common because hypothyroidism is a clearly diagnosed condition with a known etiology in most cases.

What "Severity Insufficient" Means for Hypothyroidism

Of 220 classified denials in our dataset, 67 are tagged "severity insufficient." That's 30 percent of denials with a stated reason. The pattern is consistent.

The veteran has service-connected hypothyroidism. The Board grants the connection. The rating then comes back at 0 or 10 percent because the symptom-specific criteria for higher tiers aren't documented in the medical record.

The two sub-patterns:

Sub-pattern A (pre-2017 rule): 10 percent rating, claim for 30 percent fails. The veteran was on thyroid replacement therapy with documented fatigability, clearing the old 10 percent floor under the "continuous medication required" criterion, and the Board declined 30 percent because the record did not document constipation and mental sluggishness. This pattern cannot recur under the current code, which has no 10 percent rung and awards 30 percent for hypothyroidism without myxedema regardless of symptoms. It is retained because it explains most of the decided cases in the dataset.

Sub-pattern B: 30 percent rating, claim for 60 percent fails. The veteran has the three-symptom 30 percent presentation. The Board declines to assign 60 percent because the medical record doesn't document the muscular weakness, mental disturbance, and weight gain required for the next tier.

In both patterns, the path to the higher rating runs through specific symptom documentation. Treatment notes that mention "fatigue and weight gain" generically aren't enough; the record needs each symptom in the tier criteria to be documented with clinical specificity.

The C&P examination can sometimes capture this, but in our dataset many C&P exams treat the symptoms generically rather than engaging with the tier criteria. Treating endocrinologist records or detailed primary care notes that address the constellation directly are usually what supports the higher tiers.

What Wins Hypothyroidism Claims at the Board

A few patterns we see consistently in granted hypothyroidism cases:

Documented qualifying service for the herbicide presumption. Vietnam-era boots-on-ground service, Blue Water Navy offshore service, or qualifying Thailand or Korea DMZ service. The DD-214 and personnel records establish the threshold. Once qualifying service is documented and the diagnosis is established, the presumption does the rest.

TSH and free T4 documentation establishing the diagnosis. Lab results showing elevated TSH and low or normal free T4 establish the underlying diagnosis defensibly. Veterans with subclinical hypothyroidism (mildly elevated TSH with normal T4) sometimes face Board skepticism about whether the condition is clinically significant; symptom documentation matters more in these cases.

A named residual inventory, placed in a body system. This replaces the old symptom-constellation strategy entirely. Because both current rungs expire after six months, the records that decide the durable rating are the ones documenting residual effects and the body system they belong to: depression or cognitive slowing under § 4.130, eye involvement separately under § 4.79 per Note (3), GI residuals under § 4.114, persistent bradycardia or hypotension under § 4.104. The C&P examination should be asked to identify residuals by system, not to tick symptoms off a thyroid checklist.

Diagnosis documentation and the myxedema question. Under the current code a confirmed hypothyroidism diagnosis without myxedema is worth 30 percent for six months without any symptom showing, so the diagnosis date is what starts the clock. Where myxedema is clinically present, the record should say so in those terms and identify the date of crisis stabilization, because Note (1) runs the 100 percent evaluation for six months past that date.

Strong nexus opinion when on the direct lane. For veterans whose service doesn't qualify for the herbicide presumption, the nexus opinion needs to engage with the specific exposure or in-service event that caused the hypothyroidism. The 97.2 percent strong-nexus grant rate is what's available when the opinion is well-developed.

Bottom Line

Hypothyroidism is rated under 38 CFR § 4.119 DC 7903, which since 2017-12-10 has exactly two rungs: 100 percent for hypothyroidism manifesting as myxedema, and 30 percent without it. No symptom constellation is required for either, the 10 and 60 percent tiers were deleted, and both surviving rungs expire after six months, at which point VA rates residual effects under other body systems. That makes the residual inventory the claim, and it is why the old advice to stack fatigability, constipation, and mental sluggishness is now wasted effort. In our BVA dataset of 549 cases, decided almost entirely under the repealed ladder, the grant rate is 40.4 percent. The Agent Orange / herbicide presumption added hypothyroidism in 2021 and now drives the difference between the 64.5 percent presumptive grant rate and the 38.9 percent direct rate. Camp Lejeune, radiation, and Gulf War lanes apply in narrower contexts. The most common denial pattern in the dataset is "severity insufficient," a product of the repealed conjunctive tiers. For veterans with qualifying Vietnam-era service whose hypothyroidism was denied before the 2021 expansion, the supplemental claim path is the structural opening that wasn't available under earlier versions of the framework.

Methodology and Limitations

• Data source: 38 CFR § 4.119 DC 7903, 38 USC § 1116 (Agent Orange), 38 CFR § 3.309(e) (Agent Orange presumptive list), 38 USC § 1710(e) and 38 CFR § 3.307(a)(7) (Camp Lejeune), 38 CFR § 3.311 (radiation), 38 CFR § 3.317 (Gulf War), 38 CFR § 3.156 (supplemental claims), and Claim Raven's analysis of BVA decisions tagged with hypothyroidism as the primary condition.
• Sample size: 549 BVA decisions involving hypothyroidism as the primary condition. Outcomes split granted 40.4% (222), denied 49.2% (270), remanded 10.4% (57). Connection-type, nexus-quality, denial-reason, and rating-tier breakdowns are coded from the Board's discussion in each decision.
• Limitations: The 2021 Agent Orange presumption expansion is recent; our dataset includes cases decided both before and after the expansion, and the presumption framework controls for cases decided after enactment. Subclinical hypothyroidism (mildly elevated TSH with normal T4) is treated inconsistently across BVA decisions. The 549 decisions predate the criteria on this page. They applied the pre-2017 conjunctive symptom tiers, so their rating distribution and "severity insufficient" denial share describe a repealed standard and are not a forecast under the current code. The current code also leaves open how VA identifies and stages residuals once the six-month rungs expire, which is now the main source of variation. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.